HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial public offering as early as this year, Amber Tong, Manuel Baigorri and Michelle Davis of Bloomberg reported. The company has reportedly engaged in discussions with investment banks to assess a potential IPO that could raise several hundred million dollars, according to sources familiar with the matter. HistoSonics is said to be targeting a valuation in the range of several billion dollars for the listing.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $165 from $170 at Raymond James
- Johnson & Johnson price target lowered to $155 from $170 at Stifel
- Johnson & Johnson price target lowered to $159 from $160 at BofA
- Johnson & Johnson price target lowered to $163 from $175 at Morgan Stanley
- Johnson & Johnson price target lowered to $158 from $160 at Bernstein